艾瑞思姆科技 IRTC

Mr. Quentin S. Blackford has served as our President and Chief Executive Officer and a member of our Board of Directors since October 2021. DexCom Inc., a company that develops, manufactures, produces, and distributes continuous glucose monitoring systems for diabetes management; Various roles, the most recent one as the Chief Operating Officer (September 2017 to September 2021); NuVasive, Inc., a medical device company for minimally invasive spine surgery; Various roles, the most recent one as the Chief Financial Officer (February 2009 to September 2017); Zimmer Holdings, Inc., a medical device company; Various roles, the most recent one as the Director of Finance and Controller of the Dental Division (June 1999 to September 2009); Other Public Company Directorships; Alphatec Holdings, Inc. (since October 2017); Paragon 28, Inc. (August 2022 to April 2025, when the company was acquired by Zimmer Biomet); Education; Certified Public Accountant (inactive); Dual B.S. degrees in Accounting and Business Administration, Grace College

Mr. Chad Patterson has served as our Chief Commercial Officer since July 2022. From January 2021 to July 2022, Career Highlights - iRhythm Technologies: Chief Commercial & Product Officer (June 2025 to present); Chief Commercial Officer (July 2022 to June 2025). DexCom, Inc.: Senior Vice President, Global Marketing and Product Management (March 2020 to January 2021); Vice President, Global Marketing and Product Management (March 2019 to March 2020); Senior Director, Global Consumer Marketing (March 2018 to March 2019); Director of Marketing (November 2015 to February 2018). Nestle, a manufacture of food products: Held various global management position (2005 to 2015). Education - M.B.A., Marshall School of Business at the University of Southern California; B.A. in Marketing, Entrepreneurship and Intemational Business, Gonzaga University.

Mr. Daniel G. Wilson was promoted to Chief Financial Officer in August 2024. Penumbra, Inc., a global healthcare company focused on innovative therapies: Director and Head of Business Development. J.P. Morgan: Various positions, most recently as Executive Director in the Healthcare Investment Banking group, focused on digital health, medical technology and emerging healthcare companies (August 2006 to May 2016). Piper Jaffray: Held various positions in the Healthcare Investment Banking group (August 2004 to August 2006). KPMG: Audit Associate (September 2003 to August 2004). Education - B.S. in Business Administration, California Polytechnic State University at San Luis Obispo.

Mr. Kevin O'Boyle brings over 20 years of executive leadership experience, most notably as Executive Vice President and Chief Financial Officer at NuVasive, where he helped grow the company's market capitalization from 100 million to 2 billion. Career Highlights - Advanced BioHealing Inc., Senior Vice President and Chief Financial Officer (December 2010 to July 2011, when it was acquired by Shire Pharmaceuticals); NuVasive, Inc., Executive Vice President and Chief Financial Officer, where he helped grow the company's market capitalization from $100 million to $2 billion (January 2003 to December 2009); Chroma Vision Medical Systems, Inc. (1996 to 2002), Chief Financial Officer; Chief Operating Officer; Other Public Company Directorships - Outset Medical (since May 2025); Carlsmed (since July 2024); Nevro (March 2019 to April 2025, when it was acquired by Globus Medical); GenMark Diagnostics (Chairman from 2020) (March 2010 to May 2021, when it was acquired by Roche); Wright Medical Group (Audit Committee Chair) (June 2010 to November 2020, when it was acquired by Stryker); ZELTIQ Aesthetics (July 2011 to April 2017, when it was acquired by Allergan); Education - Completed Executive Management studies at UCLA Anderson School of Management; B.S. in Accounting, Rochester Institute of Technology

Ms. Karen K. McGinnis, C.P.A. is an accomplished senior executive and board member with over three decades of experience leading complex international companies across biotechnology, consumer electronics, semiconductor, and technology industries. Career Highlights - Illumina, Inc., a leader in sequencing- and array-based solutions for genetic and genomic analysis, Chief Accounting Officer (November 2017 to April 2021); Mad Catz Interactive Inc., Chief Executive Officer and President (February 2016 to March 2017); Mad Catz Interactive Inc., Chief Financial Officer (June 2013 to February 2016); Cymer, Inc., Chief Accounting Officer (November 2009 to June 2013); Insight Enterprises, Inc., Chief Accounting Officer (September 2006 to March 2009); Insight Enterprises, Inc., Senior Vice President of Finance (2001 to September 2006); Insight Enterprises, Inc., Vice President of Finance (2000 to 2001); Other Public Company Directorships - Absci Corporation, a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design (since August 2020); Alphatec Holdings, Inc., a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery (since June 2019); Sonendo, Inc., a medical technology company (October 2021 to March 2024); Notable Other Engagements - Biosplice Therapeutics, Inc., a clinical-stage biotechnology company, Director (April 2021 to March 2023); Education - Certified Public Accountant; B.B.A. in Accounting, University of Oklahoma.

Mr. Abhijit Y. Talwalkar, Career Highlights- LSI Corporation, a leading provider of silicon, systems and software technologies for the storage and networking markets; President and Chief Executive Officer (May 2005 to May 2014); Intel Corporation; Corporate Vice President and Co-General Manager of the Digital Enterprise Group, which was comprised of Intel's business client, server, storage and communications business (1996 to 2005); Vice President and General Manager for the Intel Enterprise Platform group (1993 to 1996); Sequent Computer Systems, a multiprocessing computer systems design and manufacturer; Held senior engineering and marketing positions; Bipolar Integrated Technology, Inc., a VLSI bipolar semiconductor company; Held senior engineering and marketing positions; Lattice Semiconductor Inc., a service-driven developer of programmable design solutions; Held senior engineering and marketing positions; Other Public Company Directorships; Advanced Micro Devices, a leading provider of high-performance computing, graphics and visualization solutions (since August 2017); TE Connectivity Ltd. (since March 2017), and served as an advisor to the Board of Directors (August 2016 to March 2017); Lam Research Corporation (since 2011); LSI Corporation (May 2005 to May 2014); Notable Other Engagements; Chairman of the Bay Area chapter of Friends of the Children, a nationwide non-profit organization (since January 2015); Member of the U.S. Semiconductor Industry Association (May 2005 to May 2014); Education; B.S. in Electrical Engineering, Oregon State University

Mr. Brian B. Yoor has served as a member of our Board of Directors since June 2023. Mr. Yoor spent most of his career at Abbott Laboratories, where he last served as Chief Financial Officer. Career Highlights - Abbott Laboratories, Chief Financial Officer; Division Controller for multiple business units; Vice President of Investor Relations; Portal Innovations, a venture capital company for early life science start-ups, Founding Chairman and an Operating Partner; Notable Other Engagements - Member of the Board of Directors, 32 BioSciences (formerly Covira Surgical), a health-tech company in the microbiome space; Confluent Medical, a private equity medical device manufacturer, Audit Committee Chair; Education - Bachelor of Business Administration in Accounting, University of Toledo

Mr. Bruce G. Bodaken has served as a member of our Board of Directors since July 2017. Career Highlights; Blue Shield of California; Chairman and Chief Executive Officer, where he was responsible for strategy and management of California's third largest insurer (2000 to 2012); President and Chief Operating Officer (January 1996 to December 2000); University of California, Berkeley; Professor in the Department of Public Health; The Brookings Institution; Visiting Fellow, focused on value-based care; Other Public Company Directorships; Rite Aid Corporation (May 2013 to August 2024); Education; MA in Philosophy, University of Colorado; B.A. in Philosophy, Colorado State University.

Ms. Karen L. Ling has served as a member of our Board of Directors since November 2021. Career Highlights - American International Group, Inc., Executive Vice President and Chief Human Resources Officer, where she oversaw all aspects of human capital management, including talent acquisition, training, development, compensation and benefits, and diversity and inclusion (July 2019 to May 2021); Allergan pic, a pharmaceutical company, Executive Vice President and Chief Human Resources Officer, where she developed and oversaw a global human resources strategy (March 2015 to July 2019); Actavis plc, Senior Vice President and Chief Human Resources Officer (prior to its acquisition of Allergan pic); Forest Laboratories, Inc., Senior Vice President and Chief Human Resources Officer (January 2014 to March 2015); Merck & Co., Inc., Senior Vice President, Human Resources, Global Human Health and Consumer Care business; Schering-Plough, Group Vice President, Global Compensation & Benefits; Wyeth, Spent 14 years in various positions of increasing responsibility, developing human resources strategies for business units and working in Wyeth's Labor & Employment department; Other Public Company Directorships - Bausch + Lomb, served as the Chair of their Talent and Compensation Committee (since February2024); Galderma SA (since March 2022); Education - Juris Doctor, Boston University School of Law; B.A. in Economics, Yale University.

Dr. Cathleen Noel Bairey Merz, M.D. has served as a member of our Board of Directors since April 2018. Career Highlights- Cedars-Sinai Medical Center, in Los Angeles; Medical Director and Endowed Chair of the Barbra Streisand Women's Heart Center at the Smidt Heart Institute (2001 to present); Medical Director of the Preventive and Rehabilitative Center (1991 to present); Professor of Medicine; University of California at Los Angeles; Professor of Medicine at the David Geffen School of Medicine; Notable Other Engagements; Member of the Association of American Physicians; Member of the Association of University Cardiologists, where she served as President from 2015 to 2016; Member of the Scientific Advisory Board of CV Therapeutics, Inc., a biopharmaceutical company (2005 to 2009); Has extensive experience on non-profit boards, councils and guideline panels, including; the American College of Cardiology; the American Heart Association; the National Heart, Lung, and Blood Institute; Served on multiple editorial boards, including for the Journal of the American College of Cardiology, Circulation, and European Heart Journal; Education; Completed her training in Internal Medicine at the University of California, San Francisco, and Cardiology at Cedars-Sinai Medical Center; M.D. (Honors), Harvard Medical School; B.A. (Honors) in Biological Sciences, University of Chicago.

Mr. Mervin Smith has served as Executive Vice President of Business Operations since July 2023. In addition to other responsibilities, Career Highlights - iRhythm Technologies: Executive Vice President of Business Operations, overseeing our Global Business Services center, Clinical Operations, Manufacturing and Business Operations, in addition to other responsibilities (July 2023 to present). Zimmer Biomet, a global medical technology company: Vice President & General Manager for Surgical, Restorative Therapies & Office Based Technologies (December 2021 to January 2023); Various executive leadership roles (September 2003 to December 2021). Education - M.B.A., Ball State University; B.S. in Accounting, University of Pittsburgh.

Ms. Sumi Shrishrimal has served as our Chief Risk Officer since May 2022. From May 2018 to May 2022, Career Highlights - iRhythm Technologies: Executive Vice President, Chief Risk Officer (May 2022 to present). DexCom, Inc.: Various positions, most recently as Chief Risk Officer (May 2018 to May 2022). NuVasive, Inc.: Vice President, Internal Audit (March 2016 to May 2018); Senior Director, Internal Audit (November 2014 to February 2016). Corinthian Colleges: Various roles, most recently as Vice President, Internal Audit. Education - B.A. in Accounting and Information Systems, University of Mumbai in India.

Mr. Sean Clinton Freeman served as Executive Vice President, Strategy and Corporate Development from July 2025. Career Highlights - CeramTec Group Ag., a global medical device manufacturer: Global Head of Strategy & Business Development, where he led the formation of strategic growth priorities and inorganic initiatives (January 2024 to May 2025). NuVasive, Inc., a medical device company: Senior Vice President, Strategy & Corporate Development, where he led global strategic planning, market intelligence and inorganic growth initiatives (July 2015 to September 2023). Life Technologies, a global life sciences tools company: Head of M&A and Corporate Ventures, where he directed mergers and acquisitions activity, strategic partnerships, and established and led the corporate venture practice. Education - M.B.A., Wharton School of the University of Pennsylvania; B.Comm (Honors), University of the Witwatersrand.

Effective as of March 12, 2026, the Board of Directors of the Company appointed Jason Patten as a director of the Board. Mr. Patten currently serves as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, a role he has held since January 2022. In this capacity, he leads the company's Corporate Strategy, Strategic Partnerships, and Innovation functions, shaping initiatives that drive organizational impact and sustainable value creation. Prior to his current role, Mr. Patten held key leadership positions at UnitedHealth Group, including Chief Operating Officer and Senior Vice President of OptumHealth, where he focused on optimizing business performance and advancing operational strategy across the company's health services operations. Before joining UnitedHealth Group, Mr. Patten built a strong foundation in financial services and marketing, including global product development at MoneyGram International and strategic marketing roles at Carlson Marketing Group. Mr. Patten holds an MBA in Business Administration from University of St. Thomas and a BS in Marketing from Minnesota State University, Mankato.

Mr. Rosenbaum has served as the Company's Senior Vice President, Finance since May 2023. Prior to joining the Company, between May 2014 and May 2023, Mr. Rosenbaum served in various roles at NuVasive, Inc., including as Vice President, Corporate Controller and Chief Accounting Officer from May 2022 to May 2023, as Vice President and Corporate Controller from April 2018 to May 2022, and as Senior Director and Assistant Corporate Controller from May 2014 to March 2018. Between 2010 and May 2014, Mr. Rosenbaum held roles of increasing responsibility in the finance department of Gen-Probe, Inc. and Hologic, Inc. (which acquired Gen-Probe in August 2012), most recently serving as Hologic's Senior Director and Controller for the diagnostics division. Prior to joining Gen-Probe, Mr. Rosenbaum served as Senior Director, Finance and Accounting, at Elan Pharmaceuticals, Inc. (formerly Dura Pharmaceuticals, Inc.) from 1997 to 2010. Mr. Rosenbaum holds a bachelor's degree in Business Economics from the University of California at Santa Barbara and is a Certified Public Accountant (inactive).